Interleukin-21 as a potential therapeutic target for systemic lupus erythematosus

Molecular Biology Reports

Volumn 38, Issue 6, 2011, Pages 4077-4081

  Li, Jing ^a   Pan, Hai Feng ^a   Cen, Han ^a   Tian, Jing ^a   Ma, Yan ^a   Tao, Jin Hui ^b   Ye, Dong Qing ^a  

^a ANHUI MEDICAL UNIVERSITY   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

IL 21; Systemic lupus erythematosus; Therapeutic target

Indexed keywords

DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; INTERLEUKIN 21; INTERLEUKIN 21 RECEPTOR; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; RECOMBINANT INTERLEUKIN 21 RECEPTOR FC FUSION PROTEIN; STAT PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE SEVERITY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; NATURAL KILLER CELL; NATURAL KILLER T CELL; NONHUMAN; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE;

ANIMALS; HUMANS; INTERLEUKINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR TARGETED THERAPY; SIGNAL TRANSDUCTION;

MUS;

EID: 80052484466     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-010-0527-y     Document Type: Article

References (40)

1. Cook HT, Botto M (2006) Mechanisms of disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nat Clin Pract Rheumatol 2:330-337. (Pubitemid 43842262)
2. Parrish-Novak J, Dillon SR, Nelson A et al (2000) Interleukin 21 and its receptor are involved in NK cell expansion and regulation of lymphocyte function. Nature 408:57-63.
3. Coquet JM, Kyparissoudis K, Pellicci DG et al (2007) IL-21 is produced by NKT cells and modulates NKT cell activation and cytokine production. J Immunol 178:2827-2834. (Pubitemid 46333160)
4. Monteleone G, Pallone F, Macdonald TT (2009) Interleukin-21 (IL-21)-mediated pathways in T cell-mediated disease. Cytokine Growth Factor Rev 20:185-191.
5. Spolski R, Leonard WJ (2008) The Yin and Yang of interleukin- 21 in allergy, autoimmunity and cancer. Curr Opin Immunol 20:295-301.
6. Sawalha AH, Kaufman KM, Kelly JA et al (2008) Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 67:458-461. (Pubitemid 351498423)
7. Webb R, Merrill JT, Kelly JA et al (2009) A polymorphism within IL21R confers risk for systemic lupus erythematosus. Arthritis Rheum 60:2402-2407.
8. Kuchen S, Robbins R, Sims GP et al (2007) Essential role of IL-21 in B cell activation, expansion, and plasma cell generation during CD4 +T cell-B cell collaboration. J Immunol 179: 5886-5896.
9. Ozaki K, Spolski R, Ettinger R et al (2004) Regulation of B cell differentiation and plasma cell generation by IL-21, a novel inducer of Blimp-1 and Bcl-6. J Immunol 173:5361-5371. (Pubitemid 39392119)
10. Yang L, Anderson DE, Baecher-Allan C et al (2008) IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 454:350-352.
11. Maeda M, Yanagawa Y, Iwabuchi K et al (2007) IL-21 enhances dendritic cell ability to induce interferon-gamma production by natural killer T cells. Immunobiology 212:537-547. (Pubitemid 47109160)
12. Ozaki K, Kikly K, Michalovich D et al (2000) Cloning of a type I cytokine receptor most related to the IL-2 receptor beta chain. Proc Natl Acad Sci USA 97:11439-11444.
13. Monteleone G, Pallone F, Macdonald TT (2009) Interleukin-21 as a new therapeutic target for immune-mediated diseases. Trends Pharmacol Sci 30:441-447.
14. Caruso R, Fina D, Peluso I et al (2007) A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3 alpha, by gut epithelial cells. Gastroenterology 132:166-175. (Pubitemid 46108732)
15. Monteleone G, Caruso R, Fina D et al (2006) Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 55:1774-1780. (Pubitemid 44893577)
16. Jungel A, Distler JH, Kurowska-Stolarska M et al (2004) Expression of interleukin-21 receptor, but not interleukin-21, in synovial fibroblasts and synovial macrophages of patients with rheumatoid arthritis. Arthritis Rheum 50:1468-1476. (Pubitemid 38608068)
17. Distler JH, Jungel A, Kowal-Bielecka O et al (2005) Expression of interleukin-21 receptor in epidermis from patients with systemic sclerosis. Arthritis Rheum 52:856-864. (Pubitemid 40365109)
18. Hiromura Y, Kishida T, Nakano H et al (2007) IL21 administration into the nostril alleviates murine allergic rhinitis. J Immunol 179:7157-7165.
19. Ettinger R, Kuchen S, Lipsky PE (2008) The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 223:60-86. (Pubitemid 351986176)
20. Caven TH, Shelburne A, Sato J et al (2005) IL-21 dependent IgE production in human and mouse in vitro culture systems is cell density and cell division dependent and is augmented by IL-10. Cell Immunol 238:123-134.
21. Mehta DS, Wurster AL, Grusby MJ (2004) Biology of IL-21 and the IL-21 receptor. Immunol Rev 202:84-95. (Pubitemid 39576906)
22. Leonard WJ, Zeng R, Spolski R (2008) Interleukin 21: a cytokine/cytokine receptor system that has come of age. J Leukoc Biol 84:348-356.
23. Toomey JA, Gays F, Foster D et al (2003) Cytokine requirements for the growth and development of mouse NK cells in vitro. J Leukoc Biol 74:233-242. (Pubitemid 38040420)
24. Spolski R, Leonard WL (2007) Interleukin-21: basic biology and implications for cancer and autoimmunity. Annu Rev Immunol 26:57-79.
25. Gagnon J, Ramanathan S, Leblanc C et al (2007) Regulation of IL-21 signaling by suppressor of cytokine signaling-1 (SOCS1) in CD8 (+) T lymphocytes. Cell Signal 19:806-816. (Pubitemid 46275370)
26. Zeng R, Spolski R, Casas E et al (2007) The molecular basis of IL-21-mediated proliferation. Blood 109:4135-4142. (Pubitemid 46743374)
27. Strengell M, Matikainen S, Siren J et al (2003) IL-21 in synergy with IL-15 or IL-18 enhances IFN-gamma production in human NK and T cells. J Immunol 170:5464-5469. (Pubitemid 36617833)
28. Suto A, Wurster AL, Reiner SL et al (2006) IL-21 inhibits IFN-c production in developing Th1 cells through the repression of Eomesodermin expression. J Immunol 177:3721-3727. (Pubitemid 44359904)
29. Ettinger R, Sims GP, Fairhurst AM et al (2005) IL-21 induces differentiation of human naive and memory B cells into antibodysecreting plasma cells. J Immunol 175:7867-7879. (Pubitemid 41798347)
30. Pan HF, Ye DQ, Li XP (2008) Type 17 T-helper cells might be a promising therapeutic target for systemic lupus erythematosus. Nat Clin Pract Rheumatol 4:352-353. (Pubitemid 351974005)
31. Zhou L, Ivanov II, Spolski R et al (2007) IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and 23 pathways. Nat Immunol 8:967-974. (Pubitemid 47300011)
32. Korn T, Bettelli E, Gao W et al (2007) IL-21 initiates an alternative pathway to induce proinflammatory T(H) 17 cells. Nature 448:484-487. (Pubitemid 47123515)
33. Nurieva R, Yang XO, Martinez G et al (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448:480-483. (Pubitemid 47123514)
34. Bubier JA, Sproule TJ, Foreman O et al (2009) A critical role for IL-21 receptor signaling in the pathogenesis of systemic lupus erythematosus in BXSB-Yaa mice. Proc Natl Acad Sci USA 106:1518-1523.
35. Vinuesa CG, Cook MC, Angelucci C et al (2005) A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 435:452-458. (Pubitemid 40734237)
36. Mitoma H, Horiuchi T, Kimoto Y et al (2005) Decreased expression of interleukin-21 receptor on peripheral B lymphocytes in systemic lupus erythematosus. Int J Mol Med 16:609-615.
37. Grammer AC, Lipsky PE (2003) B cell abnormalities in systemic lupus erythematosus. Arthritis Res Ther 5:S22-S27. (Pubitemid 38239913)
38. Wei C, Anolik J, Cappione A et al (2007) A new population of cells lacking expression of CD27 represents a notable component of the B cell memory compartment in systemic lupus erythematosus. J Immunol 178:6624-6633. (Pubitemid 46717447)
39. Herber D, Brown TP, Liang S et al (2007) IL-21 has a pathogenic role in a lupus-prone mouse model and its blockade with IL-21R. Fc reduces disease progression. J Immunol 178:3822-3830. (Pubitemid 46417651)
40. Bubier JA, Bennett SM, Sproule TJ et al (2007) Treatment of BXSB-Yaa mice with IL21R-Fc fusion protein minimally attenuates systemic lupus erythematosus. Ann NY Acad Sci 1110: 590-601. (Pubitemid 350043049)